|
Treatment of Primary Coronary Artery Vascular Lesions With Biolimus Coated Coronary Balloon Dilation Catheter
RECRUITINGSponsored by JW Medical Systems Ltd
Actively Recruiting
SponsorJW Medical Systems Ltd
Started2024-05-10
Est. completion2025-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06385067
Summary
The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world. The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age ≥ 18 years; * Primary coronary artery stenosis with a vessel diameter of 2.0 mm to 2.75 mm; * Patients with residual stenosis of ≤ 30 percent after pretreatment and ≤ type B dissection; Patients who voluntarily participate in and sign the informed consent form, and who are willing to undergo follow-up as required by the protocol. Exclusion Criteria: * Pregnant or lactating females; * Patients with cardiogenic shock; * Patients with severe congestive heart failure or severe heart failure with NYHA class IV; * Patients with severe valvular heart disease; * Patients with a life expectancy of less than 24 months or factors that make clinical follow-up difficult; * Patients who are considered unsuitable for inclusion by the investigator for other reasons. * Those who are known to be allergic to melcrolimus and contrast media.
Conditions2
Coronary Artery DiseaseHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorJW Medical Systems Ltd
Started2024-05-10
Est. completion2025-12-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06385067